Tryp completes their Phase 2a psilocybin for IBS clinical trial training for psychotherapists at Massachusetts General Hospital.
Math over Myth is your weekly update on psychedelic stocks and ETFs, including ATAI, COMPASS, Cybin, GH Research, Mindset, Numinus, and more
Get the latest news on psychedelic stocks Cybin, Numinus, MindMed, ATAI, Mindset, Braxia, Tryp, Irwin Naturals, and Revive
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.